NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.

P. F. Engstrom*, A. B. Benson, A. Cohen, J. Doroshow, K. Kiel, J. Niederhuber, M. Roh, M. Tempero

*Corresponding author for this work

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

In summary, the committee believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The committee endorses the concept that treatment of patients on a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for managing resectable colon cancer is an en bloc resection; laparoscopic surgery should be done only in the context of a clinical trial. For patients with stage III disease, 5-FU-based adjuvant chemotherapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. The committee advocates a conservative post-treatment surveillance program for colon and rectal cancer patients. A determination of CEA should be done only if CEA was elevated at baseline and decreased following primary resection. Abdominal and pelvic CT scans should be utilized only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be considered for treatment with irinotecan or encouraged to participate in a phase I or II clinical trial.

Original languageEnglish (US)
Pages (from-to)140-175
Number of pages36
JournalOncology (Williston Park, N.Y.)
Volume10
Issue number11 Suppl
StatePublished - Nov 1 1996

Fingerprint

Practice Guidelines
Colorectal Neoplasms
Neoplasms
irinotecan
Fluorouracil
Colonic Neoplasms
Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Therapeutics
Adjuvant Chemotherapy
Rectal Neoplasms
Laparoscopy
Lung Diseases
Liver Diseases
Recurrence
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Engstrom, P. F., Benson, A. B., Cohen, A., Doroshow, J., Kiel, K., Niederhuber, J., ... Tempero, M. (1996). NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park, N.Y.), 10(11 Suppl), 140-175.
Engstrom, P. F. ; Benson, A. B. ; Cohen, A. ; Doroshow, J. ; Kiel, K. ; Niederhuber, J. ; Roh, M. ; Tempero, M. / NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. In: Oncology (Williston Park, N.Y.). 1996 ; Vol. 10, No. 11 Suppl. pp. 140-175.
@article{fb0c9bd826ef45d1bdc6bcf658362178,
title = "NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.",
abstract = "In summary, the committee believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The committee endorses the concept that treatment of patients on a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for managing resectable colon cancer is an en bloc resection; laparoscopic surgery should be done only in the context of a clinical trial. For patients with stage III disease, 5-FU-based adjuvant chemotherapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. The committee advocates a conservative post-treatment surveillance program for colon and rectal cancer patients. A determination of CEA should be done only if CEA was elevated at baseline and decreased following primary resection. Abdominal and pelvic CT scans should be utilized only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be considered for treatment with irinotecan or encouraged to participate in a phase I or II clinical trial.",
author = "Engstrom, {P. F.} and Benson, {A. B.} and A. Cohen and J. Doroshow and K. Kiel and J. Niederhuber and M. Roh and M. Tempero",
year = "1996",
month = "11",
day = "1",
language = "English (US)",
volume = "10",
pages = "140--175",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 Suppl",

}

Engstrom, PF, Benson, AB, Cohen, A, Doroshow, J, Kiel, K, Niederhuber, J, Roh, M & Tempero, M 1996, 'NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.', Oncology (Williston Park, N.Y.), vol. 10, no. 11 Suppl, pp. 140-175.

NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. / Engstrom, P. F.; Benson, A. B.; Cohen, A.; Doroshow, J.; Kiel, K.; Niederhuber, J.; Roh, M.; Tempero, M.

In: Oncology (Williston Park, N.Y.), Vol. 10, No. 11 Suppl, 01.11.1996, p. 140-175.

Research output: Contribution to journalArticle

TY - JOUR

T1 - NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.

AU - Engstrom, P. F.

AU - Benson, A. B.

AU - Cohen, A.

AU - Doroshow, J.

AU - Kiel, K.

AU - Niederhuber, J.

AU - Roh, M.

AU - Tempero, M.

PY - 1996/11/1

Y1 - 1996/11/1

N2 - In summary, the committee believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The committee endorses the concept that treatment of patients on a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for managing resectable colon cancer is an en bloc resection; laparoscopic surgery should be done only in the context of a clinical trial. For patients with stage III disease, 5-FU-based adjuvant chemotherapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. The committee advocates a conservative post-treatment surveillance program for colon and rectal cancer patients. A determination of CEA should be done only if CEA was elevated at baseline and decreased following primary resection. Abdominal and pelvic CT scans should be utilized only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be considered for treatment with irinotecan or encouraged to participate in a phase I or II clinical trial.

AB - In summary, the committee believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The committee endorses the concept that treatment of patients on a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for managing resectable colon cancer is an en bloc resection; laparoscopic surgery should be done only in the context of a clinical trial. For patients with stage III disease, 5-FU-based adjuvant chemotherapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. The committee advocates a conservative post-treatment surveillance program for colon and rectal cancer patients. A determination of CEA should be done only if CEA was elevated at baseline and decreased following primary resection. Abdominal and pelvic CT scans should be utilized only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be considered for treatment with irinotecan or encouraged to participate in a phase I or II clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=0030279528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030279528&partnerID=8YFLogxK

M3 - Article

C2 - 8953601

AN - SCOPUS:0030279528

VL - 10

SP - 140

EP - 175

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11 Suppl

ER -

Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J et al. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park, N.Y.). 1996 Nov 1;10(11 Suppl):140-175.